BIO-TECHNE CORP

Bio‑Techne insider buying shows strong confidence, with senior execs buying RSUs amid a 34% YTD gain and 52‑week high—good news for investors.

CEO Kelderman Kim’s buy‑sell move shows insider confidence in Bio‑Techne amid a Merck‑KGaA buzz—insight into stock strategy and future growth.

Bio‑Techne insider trade reveals cautious confidence: senior VP’s balanced buy‑sell on Aug 15 shows long‑term alignment, not a bullish spike.

Bio‑Techne Corp insider trade: President Steven Crouse buys 5,423 shares, selling 1,947, signaling confidence amid Merck partnership buzz.

Bio‑Techne CFO’s mixed buy‑sell trade shows confidence amid market noise, balancing short‑term liquidity with long‑term upside.

CEO Kelderman Kim’s July 28 buy of 35,000 Bio‑Techne shares at $47.60 reflects insider confidence and a balanced, long‑term strategy amid a strong rally in the life‑sciences stock.

Bio‑Techne Corp insider buying signals confidence: President Steven Crouse’s 600‑share purchase reflects bullish outlook and may boost the stock toward its 52‑week high.

Bio‑Techne insider purchase: Director Herr Amy E. adds 6,636 shares at $47.60, signaling confidence amid sector dip and potential future product launches.

Bio‑Techne insider buys reveal cautious optimism: CFO’s 62k-share purchase at $47.60 signals long‑term confidence amid earnings growth and dividend potential.

CEO Kelderman Kim’s recent buy/sell of Bio‑Techne shares signals confidence, but large option holdings raise dilution risks—watch earnings for clarity.